BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner D, Levine A, Kolho KL, Shaoul R, Ledder O. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 2014;8:1464-70. [PMID: 24958064 DOI: 10.1016/j.crohns.2014.05.010] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhao H, Zhang W, Cheng D, You L, Huang Y, Lu Y. Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch’s postulates. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1023896] [Reference Citation Analysis]
2 Li Y, Nguepi Tsopmejio IS, Diao Z, Xiao H, Wang X, Jin Z, Song H. Aronia melanocarpa (Michx.) Elliott. attenuates dextran sulfate sodium-induced Inflammatory Bowel Disease via regulation of inflammation-related signaling pathways and modulation of the gut microbiota. Journal of Ethnopharmacology 2022;292:115190. [DOI: 10.1016/j.jep.2022.115190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shentova-eneva R, Yankov I. Pediatric Ulcerative Colitis. Ulcerative Colitis [Working Title] 2022. [DOI: 10.5772/intechopen.102226] [Reference Citation Analysis]
4 Bousvaros A. Management of Pediatric Patients Hospitalized with Ulcerative. Management of Inpatient Inflammatory Bowel Disease 2022. [DOI: 10.1007/978-1-0716-1987-2_11] [Reference Citation Analysis]
5 Li S, Jin Y, Fu W, Cox AD, Lee D, Reddivari L. Intermittent antibiotic treatment accelerated the development of colitis in IL-10 knockout mice. Biomed Pharmacother 2021;146:112486. [PMID: 34891113 DOI: 10.1016/j.biopha.2021.112486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Popov J, Caputi V, Nandeesha N, Rodriguez DA, Pai N. Microbiota-Immune Interactions in Ulcerative Colitis and Colitis Associated Cancer and Emerging Microbiota-Based Therapies. Int J Mol Sci 2021;22:11365. [PMID: 34768795 DOI: 10.3390/ijms222111365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Li S, Wang T, Fu W, Kennett M, Cox AD, Lee D, Vanamala JKP, Reddivari L. Role of Gut Microbiota in the Anti-Colitic Effects of Anthocyanin-Containing Potatoes. Mol Nutr Food Res 2021;65:e2100152. [PMID: 34633750 DOI: 10.1002/mnfr.202100152] [Reference Citation Analysis]
8 Wang XQ, Chen H, Gao YZ, Huang YX, Zhang RJ, Xie J, Li Y, Huang YQ, Gou LS, Yao RQ. The Potential Immunomodulatory Properties of Levornidazole Contribute to Improvement in Experimental Ulcerative Colitis. Curr Med Sci 2021;41:746-56. [PMID: 34403100 DOI: 10.1007/s11596-021-2384-4] [Reference Citation Analysis]
9 Bitton S, Markowitz JF. Ulcerative Colitis in Children and Adolescents. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00043-8] [Reference Citation Analysis]
10 Evangelia L, Karanasou EA, Gazouli M. Gut Microbiome and Gastrointestinal Disorders. Gut Microbiome-Related Diseases and Therapies 2021. [DOI: 10.1007/978-3-030-59642-2_3] [Reference Citation Analysis]
11 Du W, Han W, Dong J. Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis. Med Hypotheses 2020;144:110211. [PMID: 33254520 DOI: 10.1016/j.mehy.2020.110211] [Reference Citation Analysis]
12 Turner D, Bishai J, Reshef L, Abitbol G, Focht G, Marcus D, Ledder O, Lev-Tzion R, Orlanski-Meyer E, Yerushalmi B, Aloi M, Griffiths AM, Albenberg L, Kolho KL, Assa A, Cohen S, Gophna U, Vlamakis H, Lurz E, Levine A. Antibiotic Cocktail for Pediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized Controlled Trial. Inflamm Bowel Dis 2020;26:1733-42. [PMID: 31833543 DOI: 10.1093/ibd/izz298] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
13 Gudi R, Suber J, Brown R, Johnson BM, Vasu C. Pretreatment with Yeast-Derived Complex Dietary Polysaccharides Suppresses Gut Inflammation, Alters the Microbiota Composition, and Increases Immune Regulatory Short-Chain Fatty Acid Production in C57BL/6 Mice. J Nutr 2020;150:1291-302. [PMID: 31879786 DOI: 10.1093/jn/nxz328] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
14 Hansen R, Meade S, Beattie RM, Auth MK, Croft N, Davies P, Devadason D, Doherty C, Epstein J, Howarth L, Kiparissi F, Muhammed R, Shivamurthy V, Spray C, Stanton MP, Torrente F, Urs A, Wilson D, Irving PM, Samaan M, Kammermeier J. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2021;70:1044-52. [PMID: 32873696 DOI: 10.1136/gutjnl-2020-322449] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
15 Green N, Lee D, Wahbeh G, Pacheco MC. Do Histologic Features Help Predict Colectomy in Pediatric Patients Presenting With Acute Severe Colitis? Pediatr Dev Pathol 2020;23:380-6. [PMID: 32511053 DOI: 10.1177/1093526620929477] [Reference Citation Analysis]
16 Ouahed J, Spencer E, Kotlarz D, Shouval DS, Kowalik M, Peng K, Field M, Grushkin-Lerner L, Pai SY, Bousvaros A, Cho J, Argmann C, Schadt E, Mcgovern DPB, Mokry M, Nieuwenhuis E, Clevers H, Powrie F, Uhlig H, Klein C, Muise A, Dubinsky M, Snapper SB. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis 2020;26:820-42. [PMID: 31833544 DOI: 10.1093/ibd/izz259] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 17.7] [Reference Citation Analysis]
17 Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, Rosen MJ, Vinks AA. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:429-39. [PMID: 31287855 DOI: 10.1093/ibd/izz143] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
18 Zhang R, Yuan S, Ye J, Wang X, Zhang X, Shen J, Yuan M, Liao W. Polysaccharide from flammuliana velutipes improves colitis via regulation of colonic microbial dysbiosis and inflammatory responses. Int J Biol Macromol 2020;149:1252-61. [PMID: 32035958 DOI: 10.1016/j.ijbiomac.2020.02.044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
19 Bitton S, Markowitz JF. Colitis, Ulcerative (Pediatric). Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.66025-7] [Reference Citation Analysis]
20 Krauthammer A, Tzivinikos C, Assa A, Miele E, Strisciuglio C, Urlep D, Serban ED, Singh A, Winter HS, Russell RK, Hojsak I, Malham M, Navas-López VM, Croft NM, Lee HM, Ledder O, Shamasneh I, Hussey S, Huynh HQ, Wine E, Shah N, Sladek M, de Meij TG, Romano C, Dipasquale V, Lionetti P, Afzal NA, Aloi M, Lee K, Martín-de-Carpi J, Yerushalmy-Feler A, Subramanian S, Weiss B, Shouval DS. Long-term Outcomes of Paediatric Patients Admitted With Acute Severe Colitis- A Multicentre Study From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis 2019;13:1518-26. [PMID: 31120524 DOI: 10.1093/ecco-jcc/jjz092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Aviello G, Singh AK, O'Neill S, Conroy E, Gallagher W, D'Agostino G, Walker AW, Bourke B, Scholz D, Knaus UG. Colitis susceptibility in mice with reactive oxygen species deficiency is mediated by mucus barrier and immune defense defects. Mucosal Immunol 2019;12:1316-26. [PMID: 31554901 DOI: 10.1038/s41385-019-0205-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
22 Schmitt H, Neufert C, Neurath MF, Atreya R. Resolution of Crohn's disease. Semin Immunopathol 2019;41:737-46. [PMID: 31552470 DOI: 10.1007/s00281-019-00756-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
23 Mishima Y, Sartor RB. Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases. J Gastroenterol 2020;55:4-14. [PMID: 31482438 DOI: 10.1007/s00535-019-01618-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
24 Breton J, Kastl A, Hoffmann N, Rogers R, Grossman AB, Mamula P, Kelsen JR, Baldassano RN, Albenberg L. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1586-93. [PMID: 30715364 DOI: 10.1093/ibd/izz006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
25 Tan LZ, Reilly CR, Steward-Harrison LC, Balouch F, Muir R, Lewindon PJ. Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis. Gut 2019;68:1533-5. [PMID: 30131321 DOI: 10.1136/gutjnl-2018-316599] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
26 Gudi R, Suber J, Brown R, Johnson BM, Vasu C. Pretreatment with yeast derived complex dietary-polysaccharide leads to suppressed gut inflammation, altered microbiota composition and increased immune regulatory short-chain fatty acid production in C57BL/6 mice.. [DOI: 10.1101/719112] [Reference Citation Analysis]
27 Monif GRG. Is ulcerative colitis a disease of a dysfunctional microbiota? Med Hypotheses 2019;131:109300. [PMID: 31443761 DOI: 10.1016/j.mehy.2019.109300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Ayers TD, Leonard-puppa E, Kader HA, Waddell J, Watkins RD, Blanchard SS, Safta AM, Rawal N. Oral Vancomycin as an Adjuvant Treatment in IBD. Crohn's & Colitis 360 2019;1. [DOI: 10.1093/crocol/otz015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Borody TJ, Clancy A. Fecal microbiota transplantation for ulcerative colitis-where to from here? Transl Gastroenterol Hepatol 2019;4:48. [PMID: 31304425 DOI: 10.21037/tgh.2019.06.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
30 Ho SM, Lewis JD, Mayer EA, Plevy SE, Chuang E, Rappaport SM, Croitoru K, Korzenik JR, Krischer J, Hyams JS, Judson R, Kellis M, Jerrett M, Miller GW, Grant ML, Shtraizent N, Honig G, Hurtado-Lorenzo A, Wu GD. Challenges in IBD Research: Environmental Triggers. Inflamm Bowel Dis 2019;25:S13-23. [PMID: 31095702 DOI: 10.1093/ibd/izz076] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
31 Garcia-Carbonell R, Yao SJ, Das S, Guma M. Dysregulation of Intestinal Epithelial Cell RIPK Pathways Promotes Chronic Inflammation in the IBD Gut. Front Immunol 2019;10:1094. [PMID: 31164887 DOI: 10.3389/fimmu.2019.01094] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
32 Bronsky J, de Ridder L, Ruemmele FM, Griffiths A, Buderus S, Hradsky O, Hauer AC. Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey. J Pediatr Gastroenterol Nutr 2019;68:676-83. [PMID: 30664566 DOI: 10.1097/MPG.0000000000002233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
33 Zhuang L, Chen H, Zhang S, Zhuang J, Li Q, Feng Z. Intestinal Microbiota in Early Life and Its Implications on Childhood Health. Genomics Proteomics Bioinformatics 2019;17:13-25. [PMID: 30986482 DOI: 10.1016/j.gpb.2018.10.002] [Cited by in Crossref: 97] [Cited by in F6Publishing: 103] [Article Influence: 24.3] [Reference Citation Analysis]
34 Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol 2019; 25(13): 1603-1617 [PMID: 30983820 DOI: 10.3748/wjg.v25.i13.1603] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
35 Abraham B, Quigley EMM. Antibiotics and probiotics in inflammatory bowel disease: when to use them? Frontline Gastroenterol 2020;11:62-9. [PMID: 31885842 DOI: 10.1136/flgastro-2018-101057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
36 Kelly CR, Ananthakrishnan AN. Manipulating the Microbiome With Fecal Transplantation to Treat Ulcerative Colitis. JAMA 2019;321:151-2. [PMID: 30644970 DOI: 10.1001/jama.2018.20397] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
37 Ihekweazu FD, Fofanova TY, Queliza K, Nagy-Szakal D, Stewart CJ, Engevik MA, Hulten KG, Tatevian N, Graham DY, Versalovic J, Petrosino JF, Kellermayer R. Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model. Gut Microbes 2019;10:504-20. [PMID: 30663928 DOI: 10.1080/19490976.2018.1560753] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
38 Ledder O. Antibiotics in inflammatory bowel diseases: do we know what we're doing? Transl Pediatr 2019;8:42-55. [PMID: 30881898 DOI: 10.21037/tp.2018.11.02] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
39 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
40 Stenke E, Bourke B, Knaus UG. NAPDH Oxidases in Inflammatory Bowel Disease. Methods Mol Biol 2019;1982:695-713. [PMID: 31172500 DOI: 10.1007/978-1-4939-9424-3_38] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
41 Zuo T, Ng SC. The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease. Front Microbiol. 2018;9:2247. [PMID: 30319571 DOI: 10.3389/fmicb.2018.02247] [Cited by in Crossref: 275] [Cited by in F6Publishing: 285] [Article Influence: 55.0] [Reference Citation Analysis]
42 Kordy K, Romeo AC, Lee DJ, Li F, Zabih S, Saavedra M, Cunningham NJ, Tobin N, Aldrovandi GM. Combination Antibiotics Improves Disease Activity and Alters Microbial Communities in Children With Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2018;67:e60-3. [PMID: 29762192 DOI: 10.1097/MPG.0000000000002034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
43 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 107] [Cited by in F6Publishing: 87] [Article Influence: 21.4] [Reference Citation Analysis]
44 Ledder O, Turner D. Antibiotics in IBD: Still a Role in the Biological Era? Inflamm Bowel Dis 2018;24:1676-88. [PMID: 29722812 DOI: 10.1093/ibd/izy067] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
45 Suskind DL, Cohen SA, Brittnacher MJ, Wahbeh G, Lee D, Shaffer ML, Braly K, Hayden HS, Klein J, Gold B, Giefer M, Stallworth A, Miller SI. Clinical and Fecal Microbial Changes With Diet Therapy in Active Inflammatory Bowel Disease. J Clin Gastroenterol 2018;52:155-63. [PMID: 28030510 DOI: 10.1097/MCG.0000000000000772] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 15.4] [Reference Citation Analysis]
46 McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther 2018;47:26-42. [PMID: 29034981 DOI: 10.1111/apt.14384] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 24.6] [Reference Citation Analysis]
47 Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nat Med. 2016;22:713-722. [PMID: 27387886 DOI: 10.1038/nm.4142] [Cited by in Crossref: 599] [Cited by in F6Publishing: 614] [Article Influence: 99.8] [Reference Citation Analysis]
48 Conrad MA, Rosh JR. Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am. 2017;64:577-591. [PMID: 28502439 DOI: 10.1016/j.pcl.2017.01.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
49 Moran C, Cherayil B. Biology and Clinical Treatment of Inflammatory Bowel Disease. Nanomedicine for Inflammatory Diseases 2017. [DOI: 10.1201/9781315152356-6] [Reference Citation Analysis]
50 Conrad MA, Wu GD, Kelsen JR. The Gut Microbiota and Inflammatory Bowel Disease. In: Mamula P, Grossman AB, Baldassano RN, Kelsen JR, Markowitz JE, editors. Pediatric Inflammatory Bowel Disease. Cham: Springer International Publishing; 2017. pp. 45-54. [DOI: 10.1007/978-3-319-49215-5_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
51 Schultz BM, Paduro CA, Salazar GA, Salazar-Echegarai FJ, Sebastián VP, Riedel CA, Kalergis AM, Alvarez-Lobos M, Bueno SM. A Potential Role of Salmonella Infection in the Onset of Inflammatory Bowel Diseases. Front Immunol 2017;8:191. [PMID: 28293241 DOI: 10.3389/fimmu.2017.00191] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
52 Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology 2017;152:327-339.e4. [PMID: 27769810 DOI: 10.1053/j.gastro.2016.10.012] [Cited by in Crossref: 453] [Cited by in F6Publishing: 467] [Article Influence: 75.5] [Reference Citation Analysis]
53 Albenberg L, Kader H, Paul A. Antibiotic Therapy. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_26] [Reference Citation Analysis]
54 Kaplan JL, Winter HS. Treatment of Acute Severe Ulcerative Colitis. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_37] [Reference Citation Analysis]
55 Lee WS, Ng RT, Chan KW, Lau YL. Variable outcome in infantile-onset inflammatory bowel disease in an Asian cohort. World J Gastroenterol 2016; 22(48): 10653-10662 [PMID: 28082818 DOI: 10.3748/wjg.v22.i48.10653] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
56 Mitrová K. News in treatment of inflammatory bowel diseases in children. Pediatr pro Praxi 2016;17:344-347. [DOI: 10.36290/ped.2016.076] [Reference Citation Analysis]
57 Nolte T. Stfm launches interprofessional leading change fellowship. Ann Fam Med. 2015;13:593. [PMID: 26553909 DOI: 10.1136/archdischild-2014-307218] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
58 Vora R, Finnamore HE, Crook K, Baillie C, Whittle E, Krishnamurthy B, Venkatesh K, Auth MK. Clinical Experience of Use of High-dose Intravenous Methylprednisolone in Children With Acute Moderate to Severe Colitis. J Pediatr Gastroenterol Nutr 2016;63:51-7. [PMID: 26756873 DOI: 10.1097/MPG.0000000000001080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
59 Kolho KL, Ainamo A. Progress in the treatment and outcome of pediatric inflammatory bowel disease patients. Expert Rev Clin Immunol. 2016;12:1337-1345. [PMID: 27322874 DOI: 10.1080/1744666x.2016.1201422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
60 Matijašić M, Meštrović T, Perić M, Čipčić Paljetak H, Panek M, Vranešić Bender D, Ljubas Kelečić D, Krznarić Ž, Verbanac D. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. Int J Mol Sci 2016;17:E578. [PMID: 27104515 DOI: 10.3390/ijms17040578] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 6.1] [Reference Citation Analysis]
61 Vindigni SM, Zisman TL, Suskind DL, Damman CJ. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol. 2016;9:606-625. [PMID: 27366227 DOI: 10.1177/1756283x16644242] [Cited by in Crossref: 109] [Cited by in F6Publishing: 112] [Article Influence: 15.6] [Reference Citation Analysis]
62 Sifuentes-Dominguez L, Patel AS. Genetics and Therapeutics in Pediatric Ulcerative Colitis: the Past, Present and Future. F1000Res 2016;5:F1000 Faculty Rev-240. [PMID: 26973787 DOI: 10.12688/f1000research.7440.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
63 Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther 2016;43 Suppl 1:27-36. [PMID: 26618923 DOI: 10.1111/apt.13436] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
64 Hansen JJ. Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases. Curr Allergy Asthma Rep. 2015;15:61. [PMID: 26306907 DOI: 10.1007/s11882-015-0562-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
65 Serban DE. Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet? Nutr Clin Pract 2015;30:760-79. [DOI: 10.1177/0884533615606898] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
66 Hansen JJ, Sartor RB. Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches. Curr Treat Options Gastroenterol. 2015;13:105-120. [PMID: 25595930 DOI: 10.1007/s11938-014-0042-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 9.9] [Reference Citation Analysis]
67 Wine E. Host–microbe interactions in the gut: lessons learned from models of inflammatory bowel diseases. LymphoSign Journal 2014;1:61-76. [DOI: 10.14785/lpsn-2014-0014] [Reference Citation Analysis]
68 Bringiotti R, Ierardi E, Lovero R, Losurdo G, Leo AD, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol 2014; 5(4): 550-559 [PMID: 25400998 DOI: 10.4291/wjgp.v5.i4.550] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]